In a labor and delivery room, one of the most common procedures is also one of the most subjective and painful: the manual vaginal exam. For decades, clinicians have relied on their fingers to assess cervical dilation and fetal station, a method prone to significant variability and patient trauma. Ciconia Medical, a San Diego-based startup founded in 2022, is building a hardware and software device called ILARA designed to replace that tactile exam with an AI-powered visual one [Luminate, August 2025].
It is a classic medtech challenge, aiming to insert an objective, data-driven layer into a deeply human, high-stakes clinical workflow. The company’s Intelligent Labor Real-Time Assessment device uses optics and computer vision to capture and analyze images of the cervix, providing standardized measurements in real time [Luminate, August 2025]. For founder and CEO Stephanie Cantor-Balan, a biomedical engineer with over 15 years of experience in lasers and optics, the mission is to make labor monitoring safer and less traumatic by removing a primary source of pain and diagnostic inconsistency [Luminate, August 2025].
The Clinical Wedge: From Fingers to Pixels
The core of Ciconia’s bet is that manual exams are a problem ripe for technological displacement. The procedure’s high inter-observer variability can lead to inconsistent assessments of labor progression, potentially affecting decisions around interventions like cesarean sections. For patients, especially those with a history of trauma, the exam itself can be a source of significant distress [Luminate, August 2025].
ILARA is positioned as a point-of-care imaging tool that automates this assessment. The device is designed to produce real-time images and quantitative measurements of key parameters like cervical dilation, which are then displayed on a clinician’s interface [Luminate, August 2025]. By applying machine learning to these images, Ciconia aims to reduce the dependency on individual provider skill and create a reproducible, digital record of labor progress. This data layer could integrate into hospital electronic health records, supporting quality metrics and more informed clinical decision-making.
A Founder's Technical Foundation
Stephanie Cantor-Balan leads the company as its solo founder and CEO. Her background provides the technical credibility for a hardware-centric venture. With more than 15 years as a biomedical engineer, patent authorship, and research conducted at MIT, she brings a deep materials and optics focus to the problem [Luminate, August 2025]. The company is estimated to have just two employees, a lean structure typical of very early-stage device developers navigating the long road to regulatory clearance and clinical validation [Crustdata].
Perhaps more critical for clinical adoption is the guidance of Chief Medical Advisor Eliezer Shalev, an Israeli gynecologist recognized as a pioneer in obstetric ultrasonography [Wikipedia]. Shalev’s credentials, including his role as Chairman of the Israeli Ministry of Health’s National Council for Gynecology, Neonatology and Genetics, lend significant weight to the company’s medical strategy [Wikipedia]. His involvement signals a focus on aligning the product with established clinical practice and research rigor.
Early Traction and the Regulatory Path
Ciconia Medical has navigated the early-stage ecosystem adeptly, securing non-dilutive support and seed capital to fund its initial development. The company is a graduate of two notable accelerators: the Luminate optics accelerator and the mHUB MedTech Accelerator [Ciconiamedical.com]. These programs typically provide funding, mentorship, and prototyping resources. The company has also attracted investment from a consortium of early-stage funds and angel groups, including the San Diego Angel Conference, NextCorps Luminate, and the Laerdal Million Lives Fund, with total disclosed funding estimated at approximately $245,000 [PitchBook].
Pre-Seed Funding | 0.245 | M USD
The company’s public presence is currently centered on product development and accelerator showcases, with no open job postings or detailed customer deployment data yet available. This is an expected profile for a pre-revenue medical device company still proving its technology. The next substantive milestones will involve initiating clinical studies to validate ILARA’s performance against the manual exam gold standard, a necessary step before seeking regulatory clearance from the FDA.
The Competitive and Commercial Landscape
Ciconia is not operating in a vacuum. The broader competitive set includes any technology aiming to digitize or standardize obstetrical measurements. Ciconia’s differentiation appears to rest on its integrated hardware-software approach, positioning ILARA as a dedicated point-of-care imaging device rather than an accessory or software overlay.
Commercialization will hinge on demonstrating a clear value proposition to hospital procurement teams. The potential arguments are multifaceted:
- Clinical outcomes. More accurate, standardized assessments could reduce unnecessary interventions and improve patient safety.
- Patient experience. Offering a less invasive, trauma-informed alternative aligns with growing institutional priorities around patient-centered care.
- Operational efficiency. Digital documentation and integration could streamline workflow and reporting.
The company will need to build evidence across all three axes to justify the capital expenditure of new hardware in cost-conscious hospital settings.
The Road Ahead and the Standard of Care
For the millions of individuals giving birth in hospitals each year, the current standard of care for monitoring labor progress remains the manual digital exam. It is a procedure performed countless times daily, relying on the clinician’s tactile sense and experience. While effective in skilled hands, its subjectivity is a well-documented limitation in obstetrical literature, and its contribution to patient pain and anxiety is often an unaddressed footnote in the birth experience.
Ciconia Medical’s next twelve months will be defined by its ability to move from prototype to pivotal clinical data. The company must secure the funding required to conduct these studies, which will be more capital-intensive than a software-only trial. A logical next step would be a seed round to finance this clinical validation work and expand the core team beyond its current lean state.
The ambition is significant: to redefine a fundamental component of maternal care for patients in labor and delivery units worldwide. Success would mean replacing a centuries-old tactile practice with a standardized, visual, and data-rich alternative. For now, Ciconia Medical is in the earliest, hardest phase of turning that vision into a regulated, clinically adopted device.
Sources
- [Luminate, August 2025] Ciconia Medical sets a new, safer standard in maternal and fetal care | https://luminate.org/ciconia-medical-sets-a-new-safer-standard-in-maternal-and-fetal-care/
- [Ciconiamedical.com] Meet the 10 MedTech Startups Graduating from the 2023 mHUB Accelerator | https://www.ciconiamedical.com/news/meet-the-10-medtech-startups-graduating-from-the-2023-mhub-accelerator
- [PitchBook] Ciconia Medical 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/523430-02
- [Crustdata] Ciconia Medical - Company Profile
- [Wikipedia] Eliezer Shalev Biography
- [Crunchbase] Ciconia Medical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ciconia-medical